“Teething Problems” Seen with FMD Implementation: No Shortages but Much Confusion
This article was originally published in The Gold Sheet
Executive Summary
There are “teething problems” in the implementation of the active substance import provisions of FMD, said one EU industry representative while another official called things “a mess” as member states and industry work to sort things out - but the feared drug shortages have not materialized as major API producing countries have ramped up at the last minute and are producing the written declarations attesting that their APIs meet EU GMP requirements.
You may also be interested in...
How Genentech Pivoted To Digital During The Pandemic
Technologies like head-mounted tablets became critical for method transfers, virtual inspections and more. Cloud-based submissions could be next …
Industry Urged To Use ICH Q12 Protocols To Ease Post-Approval Changes For Analytical Methods
Post-approval change management protocols could go a long way toward smoothing global rollout of analytical method changes, ICH Q12 expert says.
Next-Generation Sequencing For Adventitious Virus Detection Helps Speed Response To COVID-19
It's another case where the pandemic spurs adoption of ways to speed the manufacture of vaccines and biologics that have been in development for years.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: